|
| 37881140 | Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial. | Diabetes Obes Metab | 2024 |
| 37749420 | Training New DMC Members: A Call to Action. | Ther Innov Regul Sci | 2024 |
| 37952217 | Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. | Circulation | 2024 |
| 37950739 | Innovation in Event Adjudication-Human vs Machine. | JAMA Cardiol | 2024 |
| 37844669 | Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial. | Int J Cardiol | 2024 |
| 36342828 | Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway. | J Am Heart Assoc | 2023 |
| 37596725 | Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registries. | Clin Cardiol | 2023 |
| 37745930 | The evolving role of data & safety monitoring boards for real-world clinical trials. | J Clin Transl Sci | 2023 |
| 37876229 | Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. | J Am Soc Nephrol | 2023 |
| 37120538 | Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE. | Cardiovasc Diabetol | 2023 |
| 37345834 | Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. | J Am Heart Assoc | 2023 |
| 37116641 | Clinical and Echocardiographic Diversity Associated With Physical Fitness in the Project Baseline Health Study: Implications for Heart Failure Staging. | J Card Fail | 2023 |
| 37311602 | Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. | BMJ Open Diabetes Res Care | 2023 |
| 36974373 | Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial. | Diabetes Obes Metab | 2023 |
| 37039013 | Accelerated Epigenetic Aging Is Associated With Multiple Cardiometabolic, Hematologic, and Renal Abnormalities: A Project Baseline Health Substudy. | Circ Genom Precis Med | 2023 |
| 36999981 | Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial. | Clin J Am Soc Nephrol | 2023 |
| 37161691 | The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. | Diabetes Obes Metab | 2023 |
| 36889425 | Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. | Am J Kidney Dis | 2023 |
| 36751465 | Design and development of a digital shared decision-making tool for stroke prevention in atrial fibrillation. | JAMIA Open | 2023 |
| 36655422 | Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. | Diabetes Obes Metab | 2023 |
| 36651820 | The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. | Nephrol Dial Transplant | 2023 |
| 36942888 | Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE. | Diabetes Obes Metab | 2023 |
| 34331235 | Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. | Am J Cardiovasc Drugs | 2022 |
| 35677742 | Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. | J Diabetes Res | 2022 |
| 35737275 | Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist. | Cardiol Ther | 2022 |
| 35835600 | Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). | Am J Cardiol | 2022 |
| 35764796 | Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP). | NPJ Digit Med | 2022 |
| 35724306 | Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). | Diabetes Care | 2022 |
| 35394821 | Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. | Circulation | 2022 |
| 35695137 | Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials. | J Biopharm Stat | 2022 |
| 35621222 | Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. | J Am Heart Assoc | 2022 |
| 35589614 | Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. | Diabetes Obes Metab | 2022 |
| 35483761 | Impact of Polyvascular Disease and Diabetes on Limb and Cardiovascular Risk in Peripheral Artery Disease. | J Am Coll Cardiol | 2022 |
| 35850765 | Multi-dimensional characterization of prediabetes in the Project Baseline Health Study. | Cardiovasc Diabetol | 2022 |
| 36589778 | The development of a mobile app-focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials. | Stat (Int Stat Inst) | 2022 |
| 35872137 | Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health Study. | J Cardiovasc Comput Tomogr | 2022 |
| 36245651 | A <i>Post Hoc</i> Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease. | Kidney360 | 2022 |
| 35938182 | Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program. | Diabetes Obes Metab | 2022 |
| 36335914 | Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. | Circulation | 2022 |
| 35929472 | Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. | J Am Heart Assoc | 2022 |
| 36302586 | Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. | J Am Coll Cardiol | 2022 |
| 36302584 | Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. | J Am Coll Cardiol | 2022 |
| 35928933 | Understanding Study Drug Discontinuation Through EUCLID. | Front Cardiovasc Med | 2022 |
| 36151557 | Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure. | Cardiovasc Diabetol | 2022 |
| 33826709 | Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. | Cardiovasc Res | 2022 |
| 35016188 | Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. | Am J Nephrol | 2022 |
| 34985309 | Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. | Circulation | 2022 |
| 34915723 | Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. | Circ Cardiovasc Interv | 2022 |
| 35092723 | The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: Rationale and study design. | Am Heart J | 2022 |
| 34973948 | Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018. | Am Heart J | 2022 |